The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...

HIV is a lifelong infection that, without proper antiviral treatment, will kill cells of the immune system and leave individuals susceptible to infections and cancers. The longevity of this virus ...

A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...

The efficiency of HIV-1 replication hinges on the dynamic interplay between viral RNA and an array of viral and host proteins. At the core of this process is the dual role of the unspliced viral RNA, ...

A study on almost four thousand people of African descent has identified a gene that acts as natural defense against HIV by limiting its replication in certain white blood cells. This research paves ...

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...

40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...

There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...